Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 699

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 699
---
 78,016        78,486  
  Investing activities                                                                                                             
  Purchase of property, plant and equipment                                                   (4,009)       (5,691)       (1,374)  
  Purchase of intangible assets                                                                 (467)         (797)         (901)  
  Deposits in short-term investment                                                           (2,769)             —             —  
  Proceeds from disposal of property, plant and equipment                                          22            12            20  
  Net cash used in investing activities                                                       (7,223)       (6,476)       (2,255)  
  Financing activities                                                                                                             
  Dividends paid to shareholders                                                             (69,231)      (84,615)      (87,436)  
  Lease payments                                                      15                        (766)         (810)         (809)  
  Net cash used in financing activities                                                      (69,997)      (85,425)      (88,245)  
  Net increase/(decrease) in cash and cash equivalents                                         30,115      (13,885)      (12,014)  
  Effect of exchange rate changes on cash and cash equivalents                                (1,084)         (909)       (4,101)  
                                                                                               29,031      (14,794)      (16,115)  
  Cash and cash equivalents                                                                                                        
  Cash and cash equivalents at beginning of year                                               19,129        33,923        50,038  
  Cash and cash equivalents at end of year                                                     48,160        19,129        33,923  

The accompanying notes are an integral part of these consolidated financial statements.

F-63

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited

Notes to the Consolidated Financial Statements

1. General Information

Shanghai Hutchison Pharmaceuticals Limited (the “ Company”) and its wholly owned subsidiary, Shanghai Shangyao Hutchison Whampoa GSP Company Limited (together the “ Group”) are principally engaged in manufacturing, selling and distribution of prescription drug products. The Group has manufacturing plants in the People’s Republic of China (the “ PRC”) and sells mainly in the PRC.

The Company was incorporated in the PRC on April 30, 2001 as a Chinese-Foreign Equity joint venture. The Company is jointly controlled by Shanghai HUTCHMED Investment (HK) Limited (“ SHHCMI(HK)L”) and Shanghai Traditional Chinese Medicine